Navigation Links
Omeros Announces Successful Completion of PDE10 Phase 1 Multiple Ascending Dose Trial
Date:3/26/2013

ts show that OMS824, at well-tolerated doses, achieves concentrations that are anticipated to effectively inhibit PDE10 and support continuing development for the treatment of Huntington's disease, schizophrenia and other central nervous system disorders.

"These results are exciting – it appears that OMS824 is able to achieve significantly higher concentrations at the target enzyme in the brain than other PDE10 inhibitors being developed across the industry without incurring the movement abnormalities seen with those other compounds," stated Gregory A. Demopulos , M.D., chairman and chief executive officer of Omeros. "While wrapping up the Phase 1 program, we are aggressively advancing OMS824 into Phase 2 trials. Our initial focus will be Huntington's disease, for which we will be requesting orphan drug as well as Fast Track designations from the FDA, and a Phase 2a trial in patients with schizophrenia is expected to follow shortly thereafter. In addition to our progress in the OMS824 program, we plan to submit the NDA next quarter and the MAA mid-year for OMS302, our ophthalmic drug product, and we remain on track to advance our MASP-2 and PDE7 programs into the clinic in the coming months."

About Omeros' PDE10 Program
PDE10 is an enzyme that is expressed in areas of the brain linked to diseases that affect cognition and psychomotor functions, including Huntington's disease and schizophrenia. Huntington's disease is a hereditary neurodegenerative disorder that leads to movement, cognition, and behavioral abnormalities and premature death. Cognitive dysfunction is responsible for substantial disability in these diseases and is not improved by current medications. Omeros' proprietary compound OMS824 inhibits PDE10 and is being developed for the treatment of cognitive disorders. In addition to potential benefits on cognition, OMS824 could also improve psychiatric manifestations, such as the positive (e.g., halluci
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros Elucidates Mechanism of its PDE7 Inhibitors in Addiction
2. Omeros to Present at the Cowen and Company 33rd Annual Health Care Conference
3. Omeros Announces Toxicology Study Data from MASP-2 Inhibitor
4. Omeros Announces Positive OMS302 Safety Data in Phase 3 Clinical Trial
5. Omeros Announces Encouraging Data from Phase 1 Clinical Trial for PDE10 Program
6. Omeros to Present at the 24th Annual Piper Jaffray Health Care Conference
7. Omeros is Not Aware of Any Justification for Share Price Movement
8. Omeros Corporation Reports Third Quarter 2012 Financial Results
9. Omeros Responds to Misleading Announcement by Davis Wright Tremaine Concerning Settlement with Former Chief Financial Officer
10. Omeros Ophthalmology Product OMS302 Successful in Second Phase 3 Clinical Trial
11. Omeros Files Investigational New Drug Application for Lead Compound in PDE10 Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... June 30, 2015   Millar, Inc. , a ... announced the 2016 retirement of Craig Thummel , ... 12 years of service to the Company. The Company ... senior members of the Executive Management team as his ... Daugherty , currently Director of Sales and Marketing, as ...
(Date:6/30/2015)... NEW YORK , June 30, 2015 /PRNewswire/ ... a late stage pharmaceutical company focused on the ... today announced the closing of its previously announced ... stock. The underwriters also exercised their over-allotment option ... of common stock. The net proceeds ...
(Date:6/30/2015)... June 24, 2015 ... addition of the "Global Array Instruments Market ... The global array instruments market to grow at ... 2014-2019 The global array instruments market can ... microarrays, and others including tissue microarrays and cell ...
Breaking Medicine Technology:Millar, Inc. Announces Leadership Changes 2Millar, Inc. Announces Leadership Changes 3Dipexium Announces Closing of Public Offering of Common Stock 2Dipexium Announces Closing of Public Offering of Common Stock 3Global Array Instruments Market 2015-2019 - Advances in Personalized Medicines with Affymetrix, Agilent Technologies & Illumina Dominating 2
... Roche announced today the opening of a new ... Nutley, N.J. The Roche Center of Excellence produces dosage ... and Phase 1 and 2 clinical studies. The 17,000 ... compounds into medicines for clinical trials. ...
... Sept. 30, 2011 The CyberKnife Coalition ... the CyberKnife Robotic Radiosurgery System® have now been enrolled ... track prostate cancer patients treated with stereotactic ... Radiosurgery (RPCR), tracks clinical and functional outcomes of men ...
Cached Medicine Technology:Roche Opens New Center of Excellence Facility 2First Prostate Cancer Registry for Robotic Radiosurgery Patients Enrolls More than 500 Men 2
(Date:6/30/2015)... ... 2015 , ... Rocky Mountain Oils, a leading non-MLM supplier of premium ... new CEO, Mr. Darold Francis. The changes will help enhance the company’s focus on ... have come to know and respect for over eight years. , “I am thrilled ...
(Date:6/30/2015)... CA (PRWEB) , ... June 30, 2015 , ... ... the community. , Eleven physicians from Allied’s Fullerton division volunteered to help provide ... annual Super Surgery Saturday, March 21, at St. Jude Medical Center. , ...
(Date:6/30/2015)... ... June 30, 2015 , ... MJH Associates ... HRA Healthcare Research & Analytics , a consultative healthcare market research practice ... family of businesses. HRA offers quantitative and qualitative, custom and multi-client primary market ...
(Date:6/30/2015)... , ... June 30, 2015 , ... Red Hot ... in a recent online poll at http://scoutology.com/novaburgerwars and was selected as “Best ... published in August 2015. , Red Hot & Blue President Randy McCann said, “Everyone ...
(Date:6/30/2015)... ... June 30, 2015 , ... An opinion ... that fat transfer procedures had over breast implants when reconstructing breasts after a ... that “look and feel natural,” have increased sensation, and are less likely than ...
Breaking Medicine News(10 mins):Health News:Rocky Mountain Oils Adds New CEO, Announces Relocation of Operations to Orem, Utah 2Health News:Allied Anesthesia Physicians Volunteer to Help Orange County’s Uninsured During Annual Super Surgery Saturday 2Health News:Allied Anesthesia Physicians Volunteer to Help Orange County’s Uninsured During Annual Super Surgery Saturday 3Health News:HRA Healthcare Research & Analytics Welcomes 'Creative Problem Solver' as New Executive Vice President 2Health News:HRA Healthcare Research & Analytics Welcomes 'Creative Problem Solver' as New Executive Vice President 3Health News:Red Hot & Blue BBQ Restaurants Voted "Best Burger" in Virginia and "Best Barbecue" in Texas 2Health News:Red Hot & Blue BBQ Restaurants Voted "Best Burger" in Virginia and "Best Barbecue" in Texas 3Health News:Recent Article Advocating for Breast Reconstruction with Fat Transfers Successfully Outlines the Advantages of Transfer Procedures, Notes Beverly Hills Physicians 2Health News:Recent Article Advocating for Breast Reconstruction with Fat Transfers Successfully Outlines the Advantages of Transfer Procedures, Notes Beverly Hills Physicians 3
... Wake Forest University Baptist Medical Center, US, have found ... children with cancer, and thus limits the side effects ... looked into the chemotherapy given to children suffering from ... type of childhood cancer were administered very limited dosage ...
... may be used to treat the problem of severe ... palsy. ,Children suffering from cerebral palsy and other ... have the control over the salivary reflex. This condition ... from being a constant problem for parents or people ...
... Medical School say that for people whose blood pressure do ... levels. ,In a healthy normal person blood pressure ... late night, or sleep disturbances may elevate the nighttime blood ... fact such higher levels of blood pressure at night may ...
... Researchers have identified a virus that targets and kills a ... virus (VSV) can successfully target and kill glioblastoma, which is ... a form of brain tumor that is resistant to modern ... Medicine had taken nine different DNA and RNA viruses through ...
... had invented a therapeutic vaccine Cytos002-NicQb that can cure//smokers ... quit smoking. ,Swiss researchers for the study, in ... had said that the vaccine for nicotine dependence had ... trials successfully. The first phase of the study had ...
... by Harvard School of Public Health suggests that obesity ... if already existing. ,Obesity had been conclusively associated ... and certain forms of cancer. This is for the ... asthma. ,In obese people lungs are under-expanded and ...
Cached Medicine News:
... scaleable device that works with ... plasma or buffy coat. The ... must be prepared independently using ... volume and concentration factor can ...
Avitene Microfibrillar Collagen (MCH) is used in surgical procedures as an adjunct to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical....
The Ultrafoam Collagen Sponge is indicated in all surgical procedures as an adjunct to hemostasis when control by ligature or conventional procedures are ineffective or impractical....
Exclusive oxidized regenerated cellulose technology. The only oxidized regenerated cellulose hemostat line, surgicel absorbable hemostat delivers a unique combination of effectiveness, absorbability,...
Medicine Products: